Jonathan Chang
Stock Analyst at Leerink Partners
(0.64)
# 3,819
Out of 4,843 analysts
86
Total ratings
30.14%
Success rate
-19.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Upgrades: Outperform | $27 | $20.95 | +28.88% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $36.50 | +102.74% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $4.10 | +168.29% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $19.11 | +166.88% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $4.20 | +1,685.71% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $8.98 | +278.62% | 9 | Dec 7, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $8.22 | +508.27% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $39.40 | -23.86% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.38 | +769.57% | 8 | Aug 9, 2022 | |
| MRSN Mersana Therapeutics | Maintains: Outperform | $13 → $14 | $0.34 | +3,973.32% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $5.39 | +382.37% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $30.14 | +215.20% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.29 | +925.64% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $5.68 | +392.96% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $8.00 | +562.50% | 7 | Aug 5, 2021 |
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $20.95
Upside: +28.88%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $36.50
Upside: +102.74%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $4.10
Upside: +168.29%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $19.11
Upside: +166.88%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $4.20
Upside: +1,685.71%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $8.98
Upside: +278.62%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $8.22
Upside: +508.27%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $39.40
Upside: -23.86%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.38
Upside: +769.57%
Mersana Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $0.34
Upside: +3,973.32%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $5.39
Upside: +382.37%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $30.14
Upside: +215.20%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.29
Upside: +925.64%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $5.68
Upside: +392.96%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $8.00
Upside: +562.50%